Skip to main content

Table 1 HPD rates in different clinical studies

From: Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Type of cancer N° of patients HPD rate (%) Reference
Different types of cancer 131 9 [24]
NSCLC 335 13.1 [25]
Gastric cancer 36 11.1 [26]
Different types of cancer 182 6.6 [27]
NSCLC 406 13.8 [28]
NSCLC 152 25.7 [29]
HNSCC 34 29 [30]
Different types of cancer 155 4 [31]